BioArctic AB (publ) has published an article in Neurobiology of Disease describing new preclinical data for the investigational anti-a-synuclein antibody ABBV-0805. The publication includes data showing ABBV-0805?s ability to selectively target soluble toxic a-synuclein aggregates. The article entitled ABBV-0805, a novel antibody selective for soluble aggregated a-synuclein, prolongs lifespan and prevents buildup of a-synuclein pathology in mouse models of Parkinson?s disease focuses on the preclinical findings that continue to support ABBV-0805 for development in Parkinson?s disease. The data shows that ABBV-0805 selectively targets soluble toxic a-synuclein aggregates such as oligomers and protofibrils. In addition, ABBV-0805 displays a dose-dependent reduction of both soluble and insoluble a-synuclein aggregates in mice brains, preventing a-synuclein to spread, delaying motor-symptoms and prolonging the lifespan. Furthermore, binding of ABBV-0805 to pathological a-synuclein in postmortem brains of Parkinson?s disease patients has also been observed.